Themes 2020

Liquid Biopsy

Health Care Sector Icon

How do you begin to quantify the significance of liquid biopsy as an investment theme?

Liquid Biopsies are blood-based tests for three major uses: early detection of cancer in high-risk individuals, optimization of a clinician’s drug treatment decision based on specific genetic information, and monitoring of responses in patients undergoing treatment, along with detection of cancer recurrence as quickly as possible in cancer survivors. In 2020, we expect more data, pre-approvals, more products and more growth in a significant market opportunity even in the US alone. We estimate that roughly50% of cancer trials today include some components of personalized medicine and liquid biopsy tools representing a substantial actionable part of that trend.

What we’re watching:

  • Clinical data and validations
  • Reimbursement progress
  • Biopharma partnership agreements
Themes 2020

15 Themes to Focus on 2020: A Handbook for Portfolio Managers

Download the Handbook
15M

Cancer survivors in the us

1.5M

New cancer diagnoses in the us each year

>300M

People in the us that could benefit from early cancer screening tools

<5%

Estimated current penetration of patients eligible to use liquid biopsy tools as a cancer companion diagnostic

Research

Podcast

Wellness Technology Revolution With Therabody

Read More >
Ahead of the Curve®

Drug Pricing Survey Again Suggests Positive Outlook

Read More >
Ahead of the Curve®

The Price Is (Not) Right: Discounts, 340B, Access, And IRA

Read More >

Events

New York, NY

Jun 06, 2023

7th Annual Future of the Consumer Conference

Learn More >
Boston, MA

Mar 06, 2023

43rd Annual Health Care Conference

Learn More >
Arlington, VA

Feb 15, 2023

44th Annual Aerospace/Defense & Industrials Conference

Learn More >